Depression in Patients with Diabetes: Does It Impact Clinical Goals?

William A. Rush, PhD, Robin R. Whitebird, PhD, Monica R. Rush, BS, Leif I. Solberg, MD, and Patrick J. O’Connor, MD, MPH

Introduction: To examine whether depressive symptoms are associated with achievement of recommended goals for control of glucose, lipids, and blood pressure among patients with diabetes.

Methods: We used a prospective cohort study of 1223 adults with diabetes that obtained self-reported depression symptoms from a survey. Medication use was obtained from claims data, and pharmacy and clinical data were obtained by manual review of paper medical records.

Results: Diabetes patients with depression symptoms were less likely to be at their glucose goal (43% vs 50%; P = .0176) but more likely to be at their blood pressure goal (57% vs 51%; P = .0435). The association between lipids and depression symptoms was related to a lower rate for low-density lipoprotein testing (56% vs 68%; P < .0001). Treatment with antidepressants resulted in a greater percentage achieving glucose and blood pressure goals but not lipid goals.

Conclusions: Depression seems to have a variable impact on achieving these clinical goals, perhaps because the goals have differing measurement logistics and biological profiles. Further research is needed to learn whether better treatment of depressive symptoms leads to improvements in meeting diabetes clinical goals. (J Am Board Fam Med 2008;21:392–397.)
for review of their medical record. Because of the need to use antidepressant medication as a proxy for depression treatment, we excluded the 898 without pharmacy coverage, leaving 1223 for this analysis.

Adults were classified as having diabetes if they had either (1) 1 or more inpatient or 2 or more outpatient ICD9 diagnosis codes for diabetes mellitus (250.xx) within a defined 1-year period or (2) had a filled prescription for a diabetes-specific medication within the same defined 1-year period. This method of diabetes identification has been validated and has estimated sensitivity of 0.91, positive predictive value of 0.94, and specificity of 0.99.

Self-reported depression-related symptoms were identified from the survey, which asked 2 questions from the PHQ-2 screening tool for depression:

1. During the past month have you been bothered by feeling down, depressed, or hopeless?
2. During the past month, have you often been bothered by little interest or pleasure in doing things?

These 2 questions have been shown to have a high sensitivity of between 89% and 97%, with a more variable specificity (51% to 91%) for depression case-finding. We stratified respondents by those who had no positive responses to these questions versus those with one or more positive responses to the questions to create the independent variable of reported depression symptoms.

Dependent variables included levels of glycohemoglobin (A1c), low-density lipoprotein (LDL), systolic blood pressure (SBP), and diastolic blood pressure (DBP). These data were obtained by manual review of paper medical records and were collected for the 1-year period after the survey. These measures were classified in 2 ways:

1. Was a measurement available within the study year, and
2. Was the patient at the desired goal for the particular clinical measure (A1c ≤ 7.0; LDL ≤ 100; SBP ≤ 130; DBP ≤ 80) in each defined year.

No data were collected from the medical record review relative to depression status.

Bivariate comparisons were performed using t tests and χ² statistics, as appropriate. When multiple measures were available for a patient, the last one in the 1-year period was used in analysis. Coding of achievement of clinical goals and the presence of symptoms for depression were coded as bivariate variables. Age and gender were controlled for as of the survey date. All analyses were conducted using SAS 9.1.

Treatment with an antidepressant medication was determined by the presence of a claim for a pharmacy fill during the period of interest for a medication with a GPI group code of 58 (ie, antidepressants). Although there was no way to know whether the fill was for the treatment of depression or one of the other uses of these medications, because the subject was exhibiting symptoms of depression it seems likely that in most cases this was the intended use of the antidepressant.

Results

A comparison of the demographics of the patients responding to the survey with the subset analyzed in this study found that among the study subjects in this substudy, more were never married (7.1% vs 3.8%), fully employed (38.7% vs 28.9%), had a lower income (18.6% vs 25.1%), and had a slightly higher body mass index (31.0 vs 29.2). There were no differences in educational level, race, or Hispanic ethnic status.

Of the 1223 subjects, 471 (38.5%) reported some symptoms of depression during the past month. Table 1 contains a comparison of demographic data for the study population reporting no depression symptoms versus those indicating at least 1 depression question positively.

Among the patients reporting symptoms of depression, 36% had a diagnosis of depression in the year before the survey and 26% had a depression diagnosis in the year after the survey. Of the patients with symptoms of depression on the survey, the percentage receiving medication treatment increased from 41% to 47% between the year before and after the survey.

There was no relationship between a report of depression symptoms and A1c testing rates, but there was a pronounced relationship to being at A1c goal (Table 2). Those with depression symptoms were less likely to be at goal (43% vs 50%; P = .0176). Among the subset of patients who were
not at goal, those receiving postsurvey antidepressant medication treatment were more likely to achieve their glucose goal in the postsurvey year (48% vs 38%; P = .0517; Table 3).

<table>
<thead>
<tr>
<th>Table 1. Comparison of Sociodemographic Factors in Those With Diabetes With and Without Depressive Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Sex (%) [n]</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Marital status (%) [n]</td>
</tr>
<tr>
<td>Education (%) [n]</td>
</tr>
<tr>
<td>Employment (%) [n]</td>
</tr>
<tr>
<td>Household Income (%) [n]</td>
</tr>
<tr>
<td>LDL levels were associated with reduced testing frequency (56% vs 68%), but there were no differences in goal achievement (Table 2). Those treated with antidepressants were no more likely to have</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Relationship of Presence of Depression to Clinical Outcome Testing Rates and Goal Status in Postsurvey Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression Symptoms</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>No (%)</td>
</tr>
<tr>
<td>Yes (%)</td>
</tr>
<tr>
<td>P</td>
</tr>
</tbody>
</table>

A1c, glycohemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
either LDL testing rates or goal achievement (Table 3).

In contrast, patients with depressive symptoms were just as likely to have blood pressure testing (89% vs 90%) and more likely to have SBP (57% vs 51%; \( P = 0.1557 \)) but not DBP (45% vs 41%; \( P = 0.0435 \)) at goal. Those patients with depression symptoms who subsequently were on antidepressants were even more likely to be at SBP goal (64% vs 51%; \( P = 0.0096 \); Table 3).

**Discussion**

The presence and treatment of depression symptoms seems to have a varying impact on a patient’s ability to reach glucose, lipid, and blood pressure clinical goals. Diabetes patients with depression symptoms are less likely to achieve glucose goals, but this improves when they are treated with antidepressants. The achievement of lipid goals does not seem to be affected by the presence of depression symptoms or their treatment, although testing rates are lower in patients with depression symptoms. Only the systolic component of blood pressure was in better control in the population with depression symptoms, and this seems to improve further with treatment with antidepressants.

Why should these 3 measures behave so differently in relation to the presence of depression symptoms and treatment? One possibility is that they have differing measurement logistics and biological profiles that may impact a patient’s ability to reach important clinical goals. The glycohemoglobin (A1c) test can be taken at the clinic lab without any prior preparation and in association with any clinic visit; it is an average of the level of glucose in the blood over the prior approximately 3 months. In contrast, blood pressure is generally taken as the patient is waiting to see the physician and it is a point measurement in time with considerable variation. Taking the fasting lipid test is logistically complex, because the patient is required to fast for at least 12 hours and then travel to a blood draw site. Biologically, it represents measurements of the body’s natural lipid levels, largely independent of dietary intake.

Because A1c testing rates were high in this population (>85%) and a patient only had to have a single test within a study year to be classified as tested, it is not surprising that there was no significant difference in A1c testing rates. Because A1c is a measure of control over an extended period of time, it is also not surprising that depression, which could be expected to lower both medication and lifestyle adherence, had a significant impact on the ability to reach goal. Further support for the impact of depression on glycemic control is provided by the difference between those with signs of depression but subsequent treatment (48% at goal) with an antidepressant and those with no antidepressant (38% at goal). These data suggest that depression symptoms make it harder to reach A1c clinical goals but that treatment with an antidepressant may ameliorate this effect.

The results for blood pressure were surprising. Although test rates did not differ by depression symptom presence, the group with symptoms of depression had a significantly higher percentage at the systolic goal. When the group with depression symptoms was examined relative to their subsequent treatment with antidepressants, the treated group had a significantly higher percentage of patients at clinical goals for both systolic (64%) and diastolic blood pressure (51%). This is clearly a finding that needs further research.

The lipid results seem to display yet a third pattern. The only clearly significant difference was found in the testing rate. Patients with signs of depression had a lower testing rate (56% vs 68%) than those without signs of depression. This may be due to the higher level of complexity involved in

### Table 3. Relationship of Presence of Antidepressant Treatment in Sample with Depression to Clinical Outcome Testing Rates and Goal Status in Postsurvey Year

<table>
<thead>
<tr>
<th>Depression Symptoms on Medication</th>
<th>Postsurvey Year Clinical Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A1c Tested</td>
</tr>
<tr>
<td>No (%)</td>
<td>81</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>82</td>
</tr>
<tr>
<td>( P )</td>
<td>.7936</td>
</tr>
</tbody>
</table>

A1c, glycohemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
preparing for and having a fasting lipid panel. For a patient experiencing symptoms of depression, fasting and travel to a lab may not be as manageable. LDL levels were not different between patients with depression symptoms and those not reporting symptoms.

To the extent that depression interferes with the ability of the patient to reach clinical goals, it increases the patient’s risk of future comorbidity. The diabetes patient who has low adherence to their diabetes management, lipid, or blood pressure medication(s) as a result of depression is placed at greater risk for both micro- and macrovascular comorbid events. Diabetes patients are not alone in being negatively impacted by the presence of depression. Studies exist that suggest that both coronary artery disease and hypertension are negatively impacted by the presence of depression.19–21

Among the limitations of this study are the reduction in the study population size necessitated by the need to get consent for chart audits and limiting the subjects to those with pharmacy coverage. We also recognize that this approach is limited in that depressed patients who are not being successfully treated at the time of the survey are more likely to report symptoms of depression, whereas patients under successful treatment for depression are less likely to report symptoms of depression. The higher percentage of patients reporting symptoms of depression in our study than found in other studies suggests that the identification method used in this study may be more sensitive than that used in other investigations. Many of the other investigations tried to limit themselves to major depressive disorder (MDD). We were more liberal and included patients reporting symptoms of depression.

The results of this study suggest that depression symptoms among diabetes patients are associated with their ability to reach some clinical goals. However, this impact varies greatly among these goals. Glycohemoglobin control is reduced in diabetes patients even though test rates are high. This may be a result of reduced adherence to medications and lifestyle adjustments. Blood pressure seems to be lower among patients with symptoms of depression and under medication treatment for depression. Depression also seems to make it harder to obtain the test results for lipids. It is simply not enough for the physician to identify depression in their diabetes patients; they need to consider how the depression symptoms and their treatment might impact the patient’s ability to reach each of their individual clinical goals.

We thank the many medical groups and their associated Institutional Review Boards that participated in the Quest study.

References


